Hair loss stem cell injection is an emerging regenerative treatment that aims to stimulate dormant or damaged hair follicles using stem cells derived from the patient's own body. Interest in this approach has grown significantly, yet it remains largely investigational in the UK, with no stem cell or exosome-based hair loss product currently holding MHRA marketing authorisation for routine clinical use. This article explains how the treatment works, what the current evidence shows, who may be suitable, the risks involved, the UK regulatory framework, and the evidence-based alternatives that patients should consider first.
Summary: Hair loss stem cell injection is an investigational regenerative procedure that uses stem cells — typically derived from the patient's own fat tissue — to try to stimulate dormant hair follicles, but no such treatment currently holds MHRA marketing authorisation for routine clinical use in the UK.
- Adipose-derived stem cells (ADSCs) are the most commonly used type; they are harvested via minor liposuction and injected into the scalp after laboratory processing.
- Stem cell and exosome hair loss preparations processed outside the body are classified as Advanced Therapy Medicinal Products (ATMPs) under UK law and require MHRA authorisation before commercial use.
- Clinical evidence is limited to small, short-term studies with high risk of bias; no large-scale randomised controlled trials have confirmed efficacy or long-term safety.
- Risks include infection, liposuction-related complications, scarring, and an undefined long-term safety profile due to the absence of robust long-term data.
- Patients should verify that any treating clinic is CQC-registered (or equivalent), that the practitioner is GMC-registered, and that cell processing occurs in MHRA- and HTA-licensed facilities.
- Evidence-based first-line options — including topical minoxidil and finasteride (in men) — should be explored with a GP or consultant dermatologist before considering experimental procedures.
Table of Contents
- What Are Stem Cell Injections for Hair Loss?
- How the Treatment Works and What the Evidence Shows
- Who May Be Suitable and What to Expect in the UK
- Risks, Side Effects and Safety Considerations
- Regulation and Availability of This Treatment in the UK
- Alternatives and When to Seek NHS or Specialist Advice
- Frequently Asked Questions
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What Are Stem Cell Injections for Hair Loss?
Stem cell injections for hair loss use undifferentiated cells — most commonly from the patient's own fat tissue — to try to stimulate dormant follicles, but no such treatment holds MHRA marketing authorisation for routine UK clinical use.
Not sure if this is normal? Chat with one of our pharmacists →
Stem cell injections for hair loss represent an emerging area of regenerative medicine that has attracted considerable interest in recent years. The treatment involves using stem cells — undifferentiated cells capable of developing into various specialised cell types — to stimulate dormant or damaged hair follicles and potentially encourage new hair growth. Unlike established pharmaceutical treatments, stem cell therapy for hair loss remains largely investigational, and it is important for patients to understand the distinction between experimental procedures and clinically validated treatments.
Several different approaches fall under the broad umbrella of 'stem cell hair treatment'. These include:
-
Adipose-derived stem cells (ADSCs): Extracted from the patient's own fat tissue, typically via a small liposuction procedure.
-
Exosome therapy: Involves injecting cell-signalling molecules derived from stem cells, rather than the cells themselves. Exosome-containing injectables are classified as unlicensed medicinal products or Advanced Therapy Medicinal Products (ATMPs) in the UK and must not be supplied or administered outside of an MHRA-authorised clinical trial.
-
Follicle unit stem cell transplantation: An experimental technique aiming to culture and reimplant hair follicle stem cells.
Platelet-rich plasma (PRP) is sometimes marketed alongside stem cell therapy but is an entirely separate treatment — PRP contains no stem cells and should not be conflated with stem cell injections.
It is worth noting that the term 'stem cell injection' is used loosely in the cosmetic industry, and not all treatments marketed under this name involve true stem cells. Advertising claims for unlicensed or unproven treatments are subject to UK Advertising Standards Authority (ASA) and CAP Code rules, and patients should approach such claims with appropriate scepticism. Seek clarity from a qualified, GMC-registered practitioner before proceeding.
Crucially, no stem cell- or exosome-based hair loss treatment currently holds marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for routine clinical use in the UK. Most adipose-derived preparations processed outside the body for use in hair loss are likely to be classified as ATMPs under UK law, requiring MHRA authorisation before they can be lawfully marketed or administered commercially. The MHRA website provides further guidance on ATMP classification and licensing requirements.
| Aspect | Details |
|---|---|
| Main treatment types | Adipose-derived stem cells (ADSCs), exosome therapy, follicle unit stem cell transplantation |
| Regulatory status (UK) | No MHRA marketing authorisation; most preparations classified as ATMPs requiring MHRA authorisation before commercial use |
| Evidence quality | Low; small trials only, no large-scale RCTs, short follow-up, high risk of bias; no NICE guideline exists |
| Typical procedure (ADSCs) | Consultation, liposuction under local anaesthetic, MHRA/HTA-licensed lab processing, scalp injection; usually one day |
| Common side effects | Scalp redness, swelling, bruising, mild headache, temporary increased shedding in first few weeks |
| Serious risks | Infection, liposuction/anaesthetic complications, scarring, allergic reactions; long-term safety unestablished |
| Key patient safeguards | Use GMC-registered practitioner; verify CQC registration; report adverse events via MHRA Yellow Card scheme |
How the Treatment Works and What the Evidence Shows
ADSCs are thought to secrete growth factors that promote blood vessel formation and extend the active hair growth phase, but clinical evidence remains limited to small, short-term studies without robust randomised controlled trials.
The theoretical basis for stem cell injections in hair loss centres on the role of follicle stem cells in the natural hair growth cycle. Hair follicles contain a reservoir of stem cells located in a region called the 'bulge area'. These cells are responsible for regenerating the follicle during each growth cycle. In conditions such as androgenetic alopecia (male or female pattern hair loss), follicle miniaturisation and stem cell dysfunction are thought to contribute to progressive hair thinning. Stem cell therapy aims to replenish or reactivate these cells, thereby restoring follicle function.
From a mechanistic standpoint, adipose-derived stem cells are believed to secrete growth factors — including vascular endothelial growth factor (VEGF) and keratinocyte growth factor (KGF) — that may promote angiogenesis (new blood vessel formation) around follicles and extend the anagen (active growth) phase of the hair cycle. These mechanisms remain under investigation and have not been definitively established in large human trials.
The clinical evidence base remains limited. A number of small-scale studies and pilot trials have reported modest improvements in hair density and reduced shedding following adipose-derived stem cell or conditioned media injections. However, the overall quality of evidence is low due to:
-
Small sample sizes and frequent absence of control or sham-treatment groups
-
Short follow-up periods (typically under 12 months), meaning long-term efficacy and durability are unknown
-
Heterogeneous treatment protocols making direct comparison between studies difficult
-
High risk of bias and possible publication bias favouring positive results
-
Absence of large-scale randomised controlled trials (RCTs)
Systematic reviews and meta-analyses published to date (including those examining adipose-derived regenerative cells and conditioned media for androgenetic alopecia) have consistently highlighted these methodological limitations and have been unable to draw firm conclusions about efficacy. Optimal treatment protocols, the number of sessions required, and whether maintenance treatments are necessary remain undefined.
There is no specific NICE guideline on stem cell injections for hair loss, reflecting the current lack of robust evidence. Patients should be aware that promising early results do not equate to proven clinical efficacy, and that independent, large-scale RCTs are needed before this treatment can be considered established.
Who May Be Suitable and What to Expect in the UK
Patients with early-to-moderate androgenetic alopecia who have not responded to first-line treatments may be considered; the procedure involves fat harvesting, laboratory processing, and scalp injection, typically completed in one day.
Currently, stem cell injections for hair loss are offered exclusively in the private sector in the UK, typically through specialist hair restoration clinics or aesthetic medicine practices. There is no standardised patient selection criteria, as the treatment is not governed by NICE clinical guidelines. However, practitioners generally consider the following factors when assessing suitability:
-
Type and stage of hair loss: Patients with early-to-moderate androgenetic alopecia may be considered more suitable than those with advanced or scarring alopecia (e.g., lichen planopilaris), where follicle destruction is irreversible.
-
Overall health status: Patients with active infections, autoimmune conditions, blood disorders, or who are pregnant or breastfeeding may not be appropriate candidates. Those taking anticoagulant medicines, or with a history of keloid scarring or immunosuppression, should discuss these factors explicitly with their practitioner.
-
Realistic expectations: Candidates must understand that results are variable and not guaranteed.
-
Previous treatments: Those who have not responded adequately to first-line treatments such as topical minoxidil or finasteride may seek stem cell therapy as an adjunct or alternative.
Before proceeding, patients are strongly advised to obtain a diagnosis and management plan from their GP or a consultant dermatologist. Trichologists may offer specialist hair and scalp assessments, but it is important to be aware that trichology is not a statutorily regulated profession in the UK — unlike medicine, nursing, or pharmacy. For diagnosis and treatment decisions, a GMC-registered doctor or NHS/private consultant dermatologist should be the primary point of contact.
In terms of the procedure itself, patients undergoing adipose-derived stem cell treatment can typically expect:
- An initial consultation and scalp assessment
- A minor liposuction procedure under local anaesthetic to harvest fat tissue — this carries its own surgical and anaesthetic risks (see Risks section below)
- Laboratory processing of the harvested cells (which may take several hours); this processing must be carried out in facilities licensed by the MHRA and, where applicable, the Human Tissue Authority (HTA)
- Injection of the processed stem cell preparation into the scalp
The entire process is usually completed within a single day, though multiple sessions may be recommended. Recovery is generally straightforward, with mild scalp tenderness and swelling resolving within a few days. Visible results, if they occur, are typically reported after three to six months.
Patients should verify that any clinic offering this treatment is registered with the Care Quality Commission (CQC) in England for the relevant regulated activities (including surgical procedures such as liposuction). Equivalent oversight bodies in Wales (Healthcare Inspectorate Wales, HIW), Scotland (Healthcare Improvement Scotland, HIS), and Northern Ireland (Regulation and Quality Improvement Authority, RQIA) fulfil similar roles. Patients should also confirm that the treating practitioner is registered with the GMC and holds appropriate credentials for the procedures being performed.
Risks, Side Effects and Safety Considerations
Common side effects include scalp redness, swelling, and temporary shedding; more serious risks include infection, liposuction complications, and an undefined long-term safety profile due to limited research.
Experiencing these side effects? Our pharmacists can help you navigate them →
As with any invasive procedure, stem cell injections for hair loss carry a range of potential risks and side effects. Because the treatment is not yet standardised or widely regulated in the UK, the safety profile can vary considerably depending on the clinic, the practitioner's qualifications, and the specific technique used. Patients should be fully informed of these risks prior to consenting to treatment.
Common and expected side effects include:
-
Scalp redness, swelling, and tenderness at injection sites
-
Temporary bruising, particularly if fat harvesting is involved
-
Mild headache or discomfort following the procedure
-
Temporary increase in hair shedding in the weeks following treatment (a recognised phenomenon also seen with PRP therapy)
Less common but more serious risks include:
-
Infection: Any breach of the skin carries infection risk; this is heightened if sterile technique is not rigorously maintained, or if cell processing occurs outside a licensed facility
-
Liposuction- and anaesthetic-related complications: Including bleeding, contour irregularity, vasovagal episodes, and, rarely, fat embolism
-
Scarring or fibrosis at the liposuction or injection site, including keloid scarring in susceptible individuals
-
Allergic or inflammatory reactions to processing agents used in cell preparation
-
Unproven long-term safety: Because large-scale, long-term studies are lacking, the cumulative safety profile of repeated stem cell injections is not yet established
There is no established link between stem cell injections and serious systemic adverse events in the published literature to date; however, the absence of evidence is not evidence of absence, particularly given the limited research available.
Patients should ensure their practitioner is GMC-registered, that the procedure is performed in an appropriately regulated clinical setting, and that cell processing takes place in MHRA- and HTA-licensed facilities. Full written information must be provided before treatment.
If you experience any of the following after treatment, act as follows:
-
For concerns or unexpected symptoms, contact your treating clinic in the first instance, or call NHS 111 for urgent medical advice.
-
If symptoms are worsening — such as increasing redness, swelling, fever, or signs of infection — attend an urgent treatment centre or A&E.
-
Call 999 immediately if you experience severe allergic reaction (anaphylaxis), chest pain, difficulty breathing, or loss of consciousness.
If you suspect you have experienced a side effect from a stem cell product or related injectable, you are encouraged to report this via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk). This applies to suspected adverse reactions to medicines, biologicals, and medical devices, and helps the MHRA monitor the safety of treatments used in the UK.
Regulation and Availability of This Treatment in the UK
No stem cell or exosome hair loss treatment currently holds MHRA marketing authorisation in the UK; substantially manipulated preparations are classified as ATMPs and may only be lawfully administered within an MHRA-authorised clinical trial.
The regulatory landscape for stem cell treatments in the UK is complex and, in some respects, still evolving. The MHRA regulates medicines and medical devices, and any stem cell product intended for clinical use must meet stringent licensing requirements.
Under current UK law, stem cell preparations that are 'substantially manipulated' — such as those processed in a laboratory — are classified as Advanced Therapy Medicinal Products (ATMPs) and require MHRA marketing authorisation before they can be marketed or administered commercially. A limited exemption exists for autologous (from the patient's own body) cells used within the same surgical procedure without substantial manipulation; however, this exemption is narrow. Adipose-derived cells processed for scalp injection are generally considered to involve non-homologous use (i.e., fat cells used for a purpose other than their original function), which means they are likely to be classified as ATMPs regardless of the degree of manipulation. Patients and practitioners should not assume that autologous use automatically exempts a preparation from MHRA licensing requirements.
Exosome-containing injectables marketed for hair loss are similarly unlicensed in the UK and must not be supplied or administered outside of an MHRA-authorised clinical trial.
The Human Tissue Authority (HTA) also plays an important role, licensing establishments that procure, process, store, or distribute human tissues and cells for human application under the Human Tissue (Quality and Safety for Human Application) Regulations 2007. Patients should confirm that any clinic offering stem cell hair treatment uses HTA-licensed facilities for cell processing and storage.
Despite this regulatory framework, enforcement in the private cosmetic sector has historically been inconsistent. Patients should be aware that:
-
No stem cell or exosome hair loss treatment currently holds MHRA marketing authorisation for routine use in the UK.
-
Treatments offered outside of a licensed clinical trial setting may not meet the same safety and quality standards as authorised medicines.
-
The Care Quality Commission (CQC) regulates healthcare providers in England; equivalent bodies operate in Wales (HIW), Scotland (HIS), and Northern Ireland (RQIA). Patients should verify that any clinic offering this treatment is registered with the appropriate regulator for the relevant regulated activities.
-
Advertising claims for stem cell or exosome hair treatments are subject to ASA/CAP Code rules; clinics must not make misleading efficacy claims for unlicensed treatments.
-
Following the UK's departure from the EU, the EMA's regulations no longer apply directly, though the MHRA has adopted broadly similar standards for ATMPs.
Patients are strongly advised to research any clinic thoroughly, verify the GMC registration of the treating practitioner, and ask explicitly whether the treatment is being offered within a registered clinical trial. Legitimate trials should hold an MHRA Clinical Trial Authorisation (CTA) and be registered on a recognised public registry such as the NIHR 'Be Part of Research' portal, ISRCTN, or ClinicalTrials.gov. The MHRA website provides guidance on how to check whether a treatment or product is authorised.
Alternatives and When to Seek NHS or Specialist Advice
Evidence-based alternatives include licensed topical minoxidil and finasteride (in men); patients should see their GP first to exclude underlying medical causes and explore all approved options before pursuing experimental treatments.
For individuals experiencing hair loss, a range of evidence-based treatments are available through both the NHS and private sector, and these should generally be considered before pursuing experimental therapies. The following options are supported by NHS and BNF guidance, depending on the underlying cause:
-
Topical minoxidil: Licensed in the UK for androgenetic alopecia (male and female pattern hair loss); available over the counter in standard formulations (e.g., 2% and 5% solutions and foam). Patients should refer to the Summary of Product Characteristics (SmPC) for their specific product for full prescribing information.
-
Oral minoxidil: Not licensed in the UK for hair loss; its use for this indication is off-label and requires a private prescription from a doctor who has assessed its suitability for the individual patient.
-
Finasteride 1 mg (e.g., Propecia): Licensed for male pattern hair loss in adult men. However, finasteride for androgenetic alopecia is considered a cosmetic indication and is not routinely prescribed on the NHS; it is generally available via private prescription only. Finasteride is not licensed for use in women and must not be used during pregnancy.
-
Hair transplant surgery: Follicular unit extraction (FUE) or follicular unit transplantation (FUT) are established surgical options, though typically available privately.
-
Platelet-rich plasma (PRP) therapy: While also not NHS-funded, PRP has a more established evidence base than stem cell injections for hair loss, though it too remains unlicensed for this indication.
-
Treatment of underlying conditions: Hair loss secondary to thyroid disorders, iron deficiency anaemia, or alopecia areata requires targeted medical management. The NICE Clinical Knowledge Summary on alopecia areata provides primary care guidance on assessment and referral.
-
Other options: Dutasteride, topical finasteride, and spironolactone (in women) are used off-label in some specialist settings; low-level laser therapy devices are available but evidence remains limited. These should only be considered under specialist guidance.
For further information on specific medicines, patients and clinicians should consult the relevant BNF monographs and EMC SmPCs. The British Association of Dermatologists (BAD) publishes patient information leaflets on male and female pattern hair loss and scarring alopecia, which provide reliable, UK-specific guidance.
Patients should seek advice from their GP in the following circumstances:
-
Sudden or rapid hair loss, which may indicate an underlying medical condition
-
Patchy hair loss, scalp inflammation, or scarring
-
Hair loss in children or adolescents
-
Suspected scarring alopecia, tinea capitis (scalp ringworm), or trichotillomania
-
Loss of eyebrows, eyelashes, or body hair
-
Hair loss associated with other symptoms such as fatigue, weight changes, skin changes, or joint pain
-
Psychological distress related to hair loss
The NHS does not routinely fund cosmetic hair loss treatments, but a GP can investigate potential medical causes and refer to a consultant dermatologist where clinically indicated. Trichologists may offer specialist hair and scalp assessments; however, trichology is not a statutorily regulated profession in the UK, and a trichologist cannot prescribe medicines or make a medical diagnosis. For diagnosis and treatment planning, a GP or consultant dermatologist should be the primary point of contact.
For those considering stem cell injections, a consultation with a consultant dermatologist is advisable before committing to any private procedure, to ensure all appropriate alternatives have been explored and that the decision is fully informed. The NHS hair loss pages provide a useful starting point for understanding causes and treatment options.
Frequently Asked Questions
Is hair loss stem cell injection available on the NHS?
Hair loss stem cell injection is not available on the NHS and is offered exclusively through private clinics in the UK. The NHS does not fund cosmetic hair loss treatments, but a GP can investigate underlying medical causes and refer to a consultant dermatologist where clinically appropriate.
How much does stem cell hair loss treatment cost in the UK?
Costs vary widely between private clinics and are not standardised, as the treatment is not regulated for routine use in the UK. Because no stem cell hair loss product holds MHRA marketing authorisation, patients should factor in both the financial cost and the investigational nature of the procedure when making a decision.
What is the difference between stem cell injections and PRP for hair loss?
Platelet-rich plasma (PRP) contains concentrated growth factors from the patient's own blood but no stem cells, making it an entirely separate treatment from stem cell injections. PRP has a more established — though still limited — evidence base for hair loss, whereas stem cell injections remain more experimental and face stricter UK regulatory requirements as Advanced Therapy Medicinal Products.
How many sessions of stem cell hair treatment are typically needed?
There is no established or standardised protocol for the number of sessions required, as optimal treatment schedules have not been defined by robust clinical trials. Some clinics recommend multiple sessions, but patients should be cautious of recommendations that are not supported by peer-reviewed evidence.
Can women have stem cell injections for hair loss?
Women are not excluded from stem cell hair loss procedures in principle, but the evidence base is similarly limited for both sexes, and no treatment is MHRA-authorised for routine use. Women who are pregnant or breastfeeding should not undergo the procedure, and all women should consult a GP or consultant dermatologist to rule out underlying medical causes — such as thyroid disorders or iron deficiency — before considering any experimental treatment.
How do I check whether a UK clinic offering stem cell hair treatment is legitimate?
Verify that the clinic is registered with the Care Quality Commission (CQC) in England — or the equivalent body in Wales (HIW), Scotland (HIS), or Northern Ireland (RQIA) — and that the treating practitioner is listed on the GMC register. You should also ask whether the treatment is being offered within an MHRA-authorised clinical trial, and confirm that cell processing takes place in MHRA- and HTA-licensed facilities.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
